Cyclosporine related adverse events in aplastic anemia patients treated with immunosuppressive therapy
Annals of Hematology · 2026
DOI: 10.1007/s00277-026-06780-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Hematology, 2026. Verfasst von Lingxiao Xing und 8 weiteren Autor:innen. Beteiligte Einrichtung: National Clinical Research Center for Blood Diseases, State Key Laboratory of Experimental Hematology, Haihe Laboratory of Cell Ecosystem, Institute …. Hauptthemen laut MEDLINE: Cyclosporine, Anemia, Aplastic, Immunosuppressive Agents. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Clinical and Translational Medicine Research Project of Chinese Academy of Medical Sciences, National High Level Hospital Clinical Research Funding, National Natural Science Foundation of China.
Themen: Patientensicherheit
Abstract (Originalsprache)
BACKGROUND: Few studies have focused on cyclosporine-related adverse events (AEs) in aplastic anemia (AA) patients undergoing immunosuppressive therapy and receive cyclosporine maintenance. MATERIALS AND METHODS: We conducted a retrospective study to analyze the relationship between cyclosporine concentrations at different time points and AEs in AA patients who received cyclosporine maintenance. Cutoff values of cyclosporine concentrations for predicting every AE were defined by receiver operating characteristic (ROC) curves respectively. RESULTS: A total of 382 patients were included. The most common AEs included hypertrichosis (72.3%), gingival hyperplasia (60.5%), hyperuricemia (62.6%), hyperlipidemia (47.0%), and elevated creatinine levels (39.9%). Patients presented with AEs were with higher C0 (trough) and C2 (peak) levels. Most of the values of C0 and C2 were in the ranges of 200-250 μg/L and 700-1000 μg/L, respectively. Patients with C0 higher than 250 μg/L or C2 higher than 1000 μg/L were more likely to develop AEs. Response rate was not associated with cyclosporine concentrations, but C0 levels below 150 μg/L or C2 levels below 500 μg/L showed lower response trend. Based on these findings, we propose a therapeutic range of 150-250 μg/L for C0 and 500-1000 μg/L for C2. This range is intended to balance maintaining therapeutic efficacy with minimizing the risk of adverse events. Then we propose a dose of 4.5-5.5 mg/kg/d for patients under 40 years old and 3.5-4.5 mg/kg/d for those over 40 years old to achieve target concentrations. CONCLUSION: In summary, we provide a comprehensive analysis of AEs associated with cyclosporine maintenance in AA patients undergoing IST. We also propose optimal cyclosporine concentration ranges and suggest age-adjusted dosing strategies to ensure both efficacy and safety. KEY MESSAGES: (1) AA Patients presented with cyclosporine associated AEs were with higher C0 (trough) and C2 (peak) levels. (2) We recommend the optimal concentration ranges as 150-250 μg/L for C0 and 500-1000 μg/L for C2 for AA patients receive cyclosporine treatment. (3) We propose a dose of 4.5-5.5 mg/kg/d for patients under 40 years old and 3.5-4.5 mg/kg/d for those over 40 years old to achieve target concentrations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Clinical Research Center for Blood Diseases, State Key Laboratory of Experimental Hematology, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sc…
- Tianjin Institutes of Health Science, Tianjin, 301600, China.
- Tianjin Institutes of Health Science, Tianjin, 301600, China. fkzhang@ihcams.ac.cn.
- Tianjin Institutes of Health Science, Tianjin, 301600, China. zhaoxin@ihcams.ac.cn.
Förderung
- Clinical and Translational Medicine Research Project of Chinese Academy of Medical Sciences
- National High Level Hospital Clinical Research Funding
- National Natural Science Foundation of China
- Natural Science Foundation of Beijing Municipality
Zitieren
APA
Xing, L., Yang, W., Fan, H., Li, J., Zhao, Y., Liang, W., Shi, J., Zhang, F., & Zhao, X. (2026). Cyclosporine related adverse events in aplastic anemia patients treated with immunosuppressive therapy. Annals of Hematology. https://doi.org/10.1007/s00277-026-06780-0
Vancouver
Xing L, Yang W, Fan H, Li J, Zhao Y, Liang W, et al. Cyclosporine related adverse events in aplastic anemia patients treated with immunosuppressive therapy. Annals of Hematology. 2026. doi:10.1007/s00277-026-06780-0
BibTeX
@article{Xing2026,
author = {Xing, Lingxiao and Yang, Wenrui and Fan, Huihui and Li, Jianping and Zhao, Yufei and Liang, Weiru and Shi, Jun and Zhang, Fengkui and Zhao, Xin},
title = {Cyclosporine related adverse events in aplastic anemia patients treated with immunosuppressive therapy},
journal = {Annals of Hematology},
year = {2026},
doi = {10.1007/s00277-026-06780-0}
}
EUVIMED